1H NMR (300 MHz, CDCl3): d 1.12 (s, 3H, CH2CMeCH2), 1.22 (d,
J = 6.9 Hz, 6H, CHMe2), 1.29 (d, J = 6.9 Hz, 6H, CHMe2), 1.34
(d, J = 6.9 Hz, 6H, CHMe2), 1.50 (d, J = 6.7 Hz, 6H, CHMe2), 1.56
(s, 1H, CH2CMeCH2), 1.75 (s, 1H, CH2CMeCH2), 2.68 (d, J =
3.6 Hz, 1H, CH2CMeCH2), 3.33–3.57 (m, 4H, CHMe2), 3.69 (d,
J = 3.1 Hz, 1H, CH2CMeCH2), 3.97–4.08 (m, 4H, NCH2), 7.25–
7.19 (m, 4H, Ar), 7.34 (t, J = 7.7 Hz, 2H, Ar). 13C NMR (75 MHz,
CDCl3): d 22.4, 23.7, 23.8, 26.6, 26.7, 28.4, 28.6, 49.5, 53.8, 72.2,
124.3, 124.4, 129.0, 129.7, 136.6, 147.1, 147.3. C.I. MS (relative
intensity): 550 (10), 496 (50), 389 (10), 347 (10), 188 (15), 146 (13),
91 (31). HRMS C.I. [M+], Calcd.: 587.23841. Actual: 587.23643.
Anal. Calcd.: C 63.37, H 7.72, N 4.77. Actual: C 63.41, H 7.80,
N 4.65. IR (KBr, cm−1) 2962, 2925, 2868, 1448, 1425, 1382, 1363,
1326, 1267, 1240, 1055, 837, 802, 758, 731, 700, 621.
gratitude is also extended to James Mok for his assistance in
this study. We also gratefully acknowledge BBSRC, Wellcome
Trust, CEM UK and GSK for support of our programme. We
acknowledge the provision of mass spectra from the EPSRC Mass
Spectrometry Service at Swansea.
References
1 For recent reviews, see: (a) W. A. Herrmann, Angew. Chem., Int. Ed.,
2002, 41, 1291–1309; D. Bourissou, O. Guerret, P. Gabbai and G.
Bertrand, Chem. Rev., 2000, 100, 39; (b) A. J. Arduengo, Acc. Chem.
Res., 1999, 32, 913; (c) R. Regitz, Angew. Chem., Int. Ed. Engl., 1996,
35, 725 and references therein.
2 For a review of Pd-NHC catalysis, see: E. Assen, B. Kantchev, C. J.
O’Brien and M. G. Organ, Angew. Chem., Int. Ed., 2007, 46, 2768–
2813.
3 For a recent review, see: B. Schlummer and U. Scholz, Adv. Synth.
Catal., 2004, 346, 1599–1626 and references therein.
4 A. J. McCarroll, D. A. Sandham, L. R. Titcomb, A. K. de K. Lewis,
F. G. N. Cloke, B. P. Davies, A. P. de Santana, W. Hiller and S. Caddick,
Mol. Diversity, 2003, 7, 115–123.
5 I. Conesa-Lerma, M. J. Cawley, F. G. N. Cloke, K. Arentsen, J. S. Scott,
S. E. Pearson, J. Hayler and S. Caddick, J. Organomet. Chem., 2005,
690, 5841–5848.
6 S. Caddick, F. G. N. Cloke, G. K. B. Clentsmith, P. B. Hitchcock, D.
McKerrecher, L. R. Titcomb and M. R. V. Williams, J. Organomet.
Chem., 2001, 617, 635–639.
7 M. S. Viciu, R. F. Germaneau, O. Navarro, E. D. Stevens and S. P.
Nolan, Organometallics, 2002, 21, 5470–5472.
General procedure for amine arylation
An oven-dried Schlenk tube was charged with an aryl halide
(1.0 mmol), an amine (1.2 mmol, 1.2 eq.), (SIPr)Pd(methallyl)Cl
(18 mg, 0.03 mmol, 3.0 mol%) and a magnetic stirrer bar, and
sealed with a septum. The flask was evacuated and backfilled with
inert gas three times, after which LHMDS (1.1 mL of 1M solution
in THF, 1.1 mmol, 1.1 eq.) was added via syringe. The mixture
was stirred until the aryl halide had been consumed, as judged by
TLC. It was diluted with ethyl acetate and filtered through a short
plug of silica. The solvent was removed in vacuo and the crude
material was purified via flash column chromatography on silica
gel using an eluent of ethyl acetate–n-hexane.
8 M. S. Viciu, O. Navarro, R. F. Germaneau, R. A. Kelly III, W. Sommer,
N. Marion, E. D. Stevens, L. Cavallo and S. P. Nolan, Organometallics,
2004, 23, 1629–1635.
9 O. Navarro, H. Kaur, P. Mahjoor and S. P. Nolan, J. Org. Chem., 2004,
69, 3173–3180.
N-(4-Methylphenyl)thiamorpholine (Table 4, entry 7). The
coupling of thiamorpholine and 4-bromotoluene was performed
using the general procedure to afford 116 mg (60◦%) of the title
10 M. S. Viciu, R. F. Germaneau and S. P. Nolan, Org. Lett., 2002, 4,
4053–4056.
11 N. Marion, O. Navarro, J. Mei, E. D. Stevens, N. M. Scott and S. P.
Nolan, J. Am. Chem. Soc., 2006, 128, 4101–4111.
12 A. C. Hillier, G. A. Grasa, M. S. Viciu, H. M. Lee, C. Yang and S. P.
Nolan, J. Organomet. Chem., 2002, 653, 69–82.
13 D. R. Jensen and M. S. Sigman, Org. Lett., 2003, 5, 63–65.
14 O. Navarro and S. P. Nolan, Synthesis, 2006, 366–367.
15 According to Scifinder search.
16 H. Christensen, S. Kiil, K. Dam-Johansen, O. Nielsen and M. B.
Sommer, Org. Process Res. Dev., 2006, 10, 762–769.
17 R. W. Bladock and A. R. Katritzky, Tetrahedron Lett., 1968, 10, 1159–
62; J. J. Sloan and R. Kewley, Can. J. Chem., 1969, 47, 3453–62.
18 J. Louie, M. S. Driver, B. C. Hamann and J. F. Hartwig, J. Org. Chem.,
1997, 62, 1268–1273.
1
compound within 10 min as a white solid (mp 40 C). H NMR
(300 MHz, CDCl3): d 2.29 (s, 3H, ArCH3), 2.75–2.79 (m, 4H,
SCH2), 3.46–3.49 (m, 4H, NCH2), 6.85 (d, J = 8.8 Hz, 2H, Ar),
7.08 (d, J = 8.8 Hz, 2H, Ar). 13C NMR (75 MHz, CDCl3): d 20.5,
27.2, 52.8, 117.7, 129.6, 129.8, 149.6. E.I. MS (relative intensity):
193 (M+, 54), 119 (100). HRMS E.I. [M+], Calcd.: 193.09197.
Actual: 193.09170. IR (KBr, cm−1): 2954, 2908, 2873, 2827, 2754,
1616, 1573, 1514, 1450, 1415, 1336, 1290, 1224, 1193, 1168, 1136,
1029, 970, 893, 819, 530.
19 J. F. Hartwig, Angew. Chem., Int. Ed., 1998, 37, 2046–2067.
20 R. W. Joyner and J. B. Pendry, Catal. Lett., 1988, 1–6.
21 S. Urgaonkar, M. Nagarajan and J. G. Verkade, J. Org. Chem., 2003,
68, 452–459.
22 J.-F. Marcoux, S. Wagaw and S. L. Buchwald, J. Org. Chem., 1997, 62,
1568–1569.
Acknowledgements
We wish to gratefully acknowledge the financial support of
AstraZeneca and EPSRC in this programme of research. Sincere
This journal is
The Royal Society of Chemistry 2008
Org. Biomol. Chem., 2008, 6, 2820–2825 | 2825
©